Gilead Sciences
GILD
$65.27
Share price
-2.70%
Change (1 day)
-24.72%
Change (1 year)
Categories
Gilead Sciences (GILD) - Total liabilities
Total liabilities on the balance sheet as of December 2023 : $39.37 B
According to Gilead Sciences's latest financial reports the company's total liabilities are $39.37 B. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Gilead Sciences - Total liabilities on balance sheet (from 2001 to 2023)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2023-12-31 | $39.37 B | -6.16% |
| 2022-12-31 | $41.96 B | -10.51% |
| 2021-12-31 | $46.88 B | -6.57% |
| 2020-12-31 | $50.18 B | 28.76% |
| 2019-12-31 | $38.97 B | -7.51% |
| 2018-12-31 | $42.14 B | -15.35% |
| 2017-12-31 | $49.78 B | 32.35% |
| 2016-12-31 | $37.61 B | 15.37% |
| 2015-12-31 | $32.60 B | 73.01% |
| 2014-12-31 | $18.84 B | 73.94% |
| 2013-12-31 | $10.83 B | -7.37% |
| 2012-12-31 | $11.69 B | 12.08% |
| 2011-12-31 | $10.43 B | 90.75% |
| 2010-12-31 | $5.47 B | 71.32% |
| 2009-12-31 | $3.19 B | 29.22% |
| 2008-12-31 | $2.47 B | 10.6% |
| 2007-12-31 | $2.23 B | 0.78% |
| 2006-12-31 | $2.21 B | 200.21% |
| 2005-12-31 | $0.73 B | 159.05% |
| 2004-12-31 | $0.28 B | -48.33% |
| 2003-12-31 | $0.55 B | -23.03% |
| 2002-12-31 | $0.71 B | 109.39% |
| 2001-12-31 | $0.34 B |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | $98.78 B | 150.87% | 🇺🇸 USA |
 Pfizer PFE | $137.21 B | 248.47% | 🇺🇸 USA |
 AbbVie ABBV | $124.31 B | 215.71% | 🇺🇸 USA |
 Eli Lilly LLY | $53.14 B | 34.96% | 🇺🇸 USA |
 Amgen AMGN | $90.92 B | 130.91% | 🇺🇸 USA |
 Biogen BIIB | $12.04 B | -69.41% | 🇺🇸 USA |
 Illumina ILMN | $4.36 B | -88.91% | 🇺🇸 USA |
 Vertex Pharmaceuticals VRTX | $5.14 B | -86.92% | 🇺🇸 USA |
 Merck MRK | $69.04 B | 75.34% | 🇺🇸 USA |